Literature DB >> 31175817

Next-Generation Preexposure Prophylaxis: Choices For Effective HIV Prevention.

Kenneth K Mugwanya1, Jared M Baeten1,2,3.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31175817      PMCID： PMC7137882          DOI： 10.1093/infdis/jiz273

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  14 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

2.  Ending the HIV Epidemic: A Plan for the United States.

Authors:  Anthony S Fauci; Robert R Redfield; George Sigounas; Michael D Weahkee; Brett P Giroir
Journal:  JAMA       Date:  2019-03-05       Impact factor: 56.272

3.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

4.  Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.

Authors:  Andrew E Grulich; Rebecca Guy; Janaki Amin; Fengyi Jin; Christine Selvey; Jo Holden; Heather-Marie A Schmidt; Iryna Zablotska; Karen Price; Bill Whittaker; Kerry Chant; Craig Cooper; Scott McGill; Barbara Telfer; Barbara Yeung; Gesalit Levitt; Erin E Ogilvie; Nila J Dharan; Mohamed A Hammoud; Stefanie Vaccher; Lucy Watchirs-Smith; Anna McNulty; David J Smith; Debra M Allen; David Baker; Mark Bloch; Rohan I Bopage; Katherine Brown; Andrew Carr; Christopher J Carmody; Kym L Collins; Robert Finlayson; Rosalind Foster; Eva Y Jackson; David A Lewis; Josephine Lusk; Catherine C O'Connor; Nathan Ryder; Emanuel Vlahakis; Phillip Read; David A Cooper
Journal:  Lancet HIV       Date:  2018-10-17       Impact factor: 12.767

5.  Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.

Authors:  Annalene Nel; Neliëtte van Niekerk; Saidi Kapiga; Linda-Gail Bekker; Cynthia Gama; Katherine Gill; Anatoli Kamali; Philip Kotze; Cheryl Louw; Zonke Mabude; Nokuthula Miti; Sylvia Kusemererwa; Hugo Tempelman; Hannelie Carstens; Brid Devlin; Michelle Isaacs; Mariëtte Malherbe; Winel Mans; Jeremy Nuttall; Marisa Russell; Smangaliso Ntshele; Marlie Smit; Leonard Solai; Patrick Spence; John Steytler; Kathleen Windle; Maarten Borremans; Sophie Resseler; Jens Van Roey; Wim Parys; Tony Vangeneugden; Ben Van Baelen; Zeda Rosenberg
Journal:  N Engl J Med       Date:  2016-12-01       Impact factor: 91.245

6.  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Authors:  David A Margolis; Juan Gonzalez-Garcia; Hans-Jürgen Stellbrink; Joseph J Eron; Yazdan Yazdanpanah; Daniel Podzamczer; Thomas Lutz; Jonathan B Angel; Gary J Richmond; Bonaventura Clotet; Felix Gutierrez; Louis Sloan; Marty St Clair; Miranda Murray; Susan L Ford; Joseph Mrus; Parul Patel; Herta Crauwels; Sandy K Griffith; Kenneth C Sutton; David Dorey; Kimberly Y Smith; Peter E Williams; William R Spreen
Journal:  Lancet       Date:  2017-07-24       Impact factor: 79.321

7.  Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.

Authors:  Eleftherios Michailidis; Emily M Ryan; Atsuko Hachiya; Karen A Kirby; Bruno Marchand; Maxwell D Leslie; Andrew D Huber; Yee T Ong; Jacob C Jackson; Kamalendra Singh; Eiichi N Kodama; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  Retrovirology       Date:  2013-06-24       Impact factor: 4.602

8.  Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.

Authors:  Jessica E Haberer; Jared M Baeten; James Campbell; Jonathan Wangisi; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Christina Psaros; Steven A Safren; Norma C Ware; Katherine K Thomas; Deborah Donnell; Meighan Krows; Lara Kidoguchi; Connie Celum; David R Bangsberg
Journal:  PLoS Med       Date:  2013-09-10       Impact factor: 11.069

9.  Use of modern contraception increases when more methods become available: analysis of evidence from 1982-2009.

Authors:  John Ross; John Stover
Journal:  Glob Health Sci Pract       Date:  2013-07-26

10.  The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention.

Authors:  Ariane van der Straten; Kawango Agot; Khatija Ahmed; Rachel Weinrib; Erica N Browne; Kgahlisho Manenzhe; Fredrick Owino; Jill Schwartz; Alexandra Minnis
Journal:  J Int AIDS Soc       Date:  2018-03       Impact factor: 5.396
View more
  1 in total

Review 1.  Long-acting injectable cabotegravir for the prevention of HIV infection.

Authors:  Meredith E Clement; Ryan Kofron; Raphael J Landovitz
Journal:  Curr Opin HIV AIDS       Date:  2020-01       Impact factor: 4.061
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.